The treatment, a selective antagonist of the lysophosphatidic acid 1 receptor PIPE-791, showed trends toward improvement on multiple exploratory efficacy endpoints, the company Thursday. Those ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results